Forest Road Acquisition Corp. (FRX) – Press Releases
-
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
-
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
-
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
-
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
-
Fennec Announces Incremental $5 Million Investment from Petrichor
-
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023
-
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
-
Fennec Announces Results of Annual Meeting
-
Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
-
Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
-
Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
-
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results
-
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
-
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
-
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States
-
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor
-
Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)
-
Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor
-
Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
-
Fennec Announces Results of Annual Meeting
-
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™
-
Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference
-
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark™
-
Fennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update
-
Fennec Pharmaceuticals Announces Management Change
-
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized
-
Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with
-
Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
-
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
-
Fennec Announces Results of Annual Meeting
-
The Beachbody Company and Myx Fitness Complete Merger with Forest Road Acquisition Corp., Creating the Leading Subscription Health and Wellness Company for the Mass Market
-
Forest Road Acquisition Corp. Stockholders Approve Proposed Merger With The Beachbody Company and Myx Fitness, Creating the Leading Subscription Health and Wellness Company for the Mass Market
-
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
-
Forest Road Acquisition Corp., The Beachbody Company and Myx Fitness Announce Expected Closing of Business Combination
-
Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™
-
The Beachbody Company Leads Investment in Feed Media Group, Premier B2B Music Licensing Platform
-
Beachbody CEO Letter to Forest Road Shareholders
-
The Beachbody Company to Participate in Baird’s 2021 Global Consumer, Technology & Services Conference
-
Forest Road Letter to Stockholders
Back to FRX Stock Lookup
